Michelle Robertson
Net Worth
Last updated:
What is Michelle Robertson net worth?
The estimated net worth of Ms. Michelle Robertson is at least $3,092,302 as of 11 May 2023. She owns shares worth $279,318 as insider, has earned $223,944 from insider trading and has received compensation worth at least $2,589,040 in Editas Medicine, Inc..
What is the salary of Michelle Robertson?
Ms. Michelle Robertson salary is $647,260 per year as Chief Financial Officer, Principal Accounting Officer, Treasurer & Assistant Sec. in Editas Medicine, Inc..
What stocks does Michelle Robertson currently own?
As insider, Ms. Michelle Robertson owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | Chief Financial Officer, Principal Accounting Officer, Treasurer & Assistant Sec. | 106,610 | $2.62 | $279,318 |
What does Editas Medicine, Inc. do?
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Michelle Robertson insider trading
Editas Medicine, Inc.
Ms. Michelle Robertson has made 12 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently she sold 949 units of EDIT stock worth $9,369 on 11 May 2023.
The largest trade she's ever made was exercising 4,287 units of EDIT stock on 13 Feb 2023. As of 11 May 2023 she still owns at least 106,610 units of EDIT stock.